Screener
Monte Rosa Therapeutics, Inc. GLUE PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
| (in thousands, except share and per share amounts) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Other receivables | 4,920 | 4,600 |
| Prepaid expenses and other current assets | 5,382 | 4,481 |
| Total current assets | 631,406 | 393,185 |
| Property and equipment, net | 29,932 | 25,986 |
| Operating lease right-of-use assets | 24,056 | 24,386 |
| Restricted cash | 4,939 | 4,954 |
| Other long-term assets | 828 | 148 |
| Total assets | $691,161 | $448,659 |
Item 1. Financial Statements
FAQ
- What is Monte Rosa Therapeutics, Inc.'s PP&E (net)?
- Monte Rosa Therapeutics, Inc. (GLUE) reported PP&E (net) of $29.93M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s PP&E (net) changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s PP&E (net) increased by 3.0% year-over-year, from $29.05M to $29.93M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s PP&E (net)?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s PP&E (net) has grown at a 41.2% compound annual growth rate (CAGR), from $4.62M to $25.99M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Monte Rosa Therapeutics, Inc.'s pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude